Why is the DAC form so much longer-acting?

It binds covalently to albumin, so its duration tracks albumin turnover (around nineteen days) rather than its own clearance.

Do the substitutions alone give a long half-life?

No. They block enzymatic cleavage but not renal filtration, which is why Modified GRF (1-29) still clears in about thirty minutes.

CJC-1295 Half-Life: DAC vs Non-DAC

The short answer

Native GHRH clears in minutes, dominated by DPP-4. Modified GRF (1-29) extends that to roughly thirty minutes by blocking DPP-4 and other cleavage sites. The DAC form extends it to days by binding covalently to albumin, which removes renal filtration as a route.

Key facts

Native GHRH: Minutes (DPP-4 dominated)
Modified GRF (1-29): ~30 minutes
CJC-1295 with DAC: Days
DPP-4 countermeasure: D-Ala at position 2
Renal countermeasure: Covalent albumin binding
Albumin half-life: ~19 days

Three clearance problems, solved in sequence

Native GHRH faces enzymatic cleavage and renal filtration. The substitutions address the first: D-alanine at position 2 makes the peptide a non-substrate for DPP-4, and three further substitutions cover other cleavage points. That alone takes it from minutes to about thirty minutes, a real gain, and still short, because the molecule remains small enough to be filtered.

Why size still matters after the substitutions

At 3367.9 Da, Modified GRF (1-29) passes the glomerulus freely. Blocking proteases does nothing about that. To extend duration further, something has to make the molecule effectively larger in circulation, which is exactly what the DAC linker achieves by attaching it to a 66 kDa protein.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

Covalent versus reversible, and why it matters here

Semaglutide's fatty acid binds albumin reversibly, maintaining an equilibrium between free and bound. DAC forms a covalent bond to albumin's cysteine-34. The peptide is not in equilibrium. It is attached, and its duration is governed by albumin turnover rather than by a dissociation constant. Albumin's half-life is around nineteen days, which is why the DAC form lasts days rather than hours.

The physiological question that creates

GHRH signalling is normally pulsatile, and a covalently albumin-bound analogue produces sustained receptor exposure instead. Whether continuous stimulation produces the same downstream result as pulses is a real question, and Ionescu and Frohman addressed it directly in 2006, reporting that pulsatile GH secretion persists during continuous stimulation, the pituitary imposing its own rhythm on a constant signal.

Why the non-DAC form is not simply inferior

A short half-life is a design choice, not a defect. If the research question concerns a brief physiological-like pulse, a compound clearing in thirty minutes models that better than one producing continuous exposure for days. Which is appropriate depends entirely on what is being studied.

Frequently asked questions

Why is the DAC form so much longer-acting?: It binds covalently to albumin, so its duration tracks albumin turnover (around nineteen days) rather than its own clearance.
Do the substitutions alone give a long half-life?: No. They block enzymatic cleavage but not renal filtration, which is why Modified GRF (1-29) still clears in about thirty minutes.
Does continuous stimulation change GH release?: Ionescu and Frohman reported that pulsatile GH secretion persists during continuous stimulation, with the pituitary imposing its own rhythm.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
▸Ghrelin-receptor binding assays for Ipamorelin analogue development
▸Analytical HPLC method development for lipidated GHRH analogues
▸Stability testing under refrigerated storage

Handling checklist

✓Store lyophilised at −20 °C long-term
✓Reconstitute in bacteriostatic water; both peptides dissolve readily
✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Half-Life: Why a Covalent Bond Changes Everything